Skip to content

Clinical trials

Myelodysplastic Syndromes trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myelodysplastic Syndromes Phase: Not applicable Clear all

127 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20014
20023
20033
20045
20056
20062
20074
20089
20093
20102
20124
20133
20146
20155
20167
20175
20182
20194
20202
202110
20226
20237
20244
20258
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed58
Recruiting23
Terminated19
Unknown status13
Active, not recruiting5
Withdrawn5
Not yet recruiting4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Masonic Cancer Center, University of Minnesota5
City of Hope Medical Center4
Dana-Farber Cancer Institute4
Fred Hutchinson Cancer Center4
Memorial Sloan Kettering Cancer Center4
Stanford University4
Institut Paoli-Calmettes3
National Heart, Lung, and Blood Institute (NHLBI)3
Rigshospitalet, Denmark3
University of Miami3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myelodysplastic Syndromes127
Leukemia, Myeloid, Acute69
Leukemia50
Precursor Cell Lymphoblastic Leukemia-Lymphoma50
Lymphoma, Non-Hodgkin43
Multiple Myeloma41
Hodgkin Disease37
Lymphoma36
Leukemia, Lymphocytic, Chronic, B-Cell34
Myeloproliferative Disorders32

Trials

Showing 76 to 100 of 127. Each trial links to its page on Pharma Observatory.

27 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.